Simultaneous intratracheal administration of surfactant and budesonide in the prevention of bronchopulmonary dysplasia in the treatment of respiratory distress syndrome in premature infants

Mandana Kashaki, Elahe Norouzi, Arezoo Aminyan Daryasari, Mahsa Maleki, Fahimeh Farhanian

Abstract


Background: Premature birth is an important issue in developing and developed countries. The purpose of this study is to investigate the effect of budesonide and surfactant in the treatment of respiratory distress syndrome and the prevention of bronchopulmonary dysplasia (BPD).

Methods: In a randomized clinical trial study, 296 premature babies with a gestational age of less than 37 weeks and weigh below 1500 grams admitted to Shahid Akbarabadi Hospital in Tehran (Iran) who were hospitalized with a diagnosis of respiratory distress syndrome and needed treatment with surfactant were included in the study. In one group (surfactant), 4 cc/kg surfactant (Braksurf) was injected intratracheally, and in the other group (surfactant + budesonide), in addition to surfactant (Braksurf), 0.25 mg/kg of budesonide was prescribed along with intratracheal surfactant. Descriptive statistics including Kaplan-Meier, Chi-square test and  t-Student test were used for data analysis.

Result: In infants who were administered budesonide with surfactant through a tracheal tube, the duration of mechanical ventilation, the duration of high-flow nasal cannula (HFNC), continuous positive airway pressure (CPAP) and the need to receive peripheral equipment or through channel The nose was significantly less than the babies who received only surfactant. In the surfactant group, 13 infants (8.7%) and in the surfactant + budesonide group, 4 infants (2.7%) had bronchopulmonary dysplasia.

Conclusion: The use of the combination of surfactant (Braksurf) with budesonide compared to surfactant alone in the treatment of premature infants significantly reduced the need for respiratory support and the need for intubation and duration of hospitalization and bronchopulmonary dysplasia.

Keywords: Budesonide; Surfactant; Premature babies; Respiratory Distress Syndrome; Bronchopulmonary dysplasia


Full Text:

PDF

References


Pan J, Chen M-W, Ni W-Q, Fang T, Zhang H, Chen Y, et al. Clinical efficacy of pulmonary surfactant combined with budesonide for preventing bronchopulmonary dysplasia in very low birth weight infants, Chinese Journal of Contemporary Pediatrics, (2017);19(2): 137-41.

Hassanzadeh-Khanmiri H, Mohammad AA, Yousif RS, Jasim SA, Kzar HH, Lafta MH, Jalil AT, Romero Parra RM, Darvishi M. SARS-CoV2 neuroinvasive potential in respiratory failure in COVID-19 patients. Caspian Journal of Environmental Sciences, (2023); 21(2): 467-472.

Karimi M, Gholami-Ahangaran M. A Brief Report on Current Evidence of Traditional Chinese Medicine in the Treatment of Patients Infected with SARS-CoV-2. Plant Biotechnology Persa, (2021); 3 (1) :34-36.

Minji Heo, Ga Won Jeon. Intratracheal administration of budesonide with surfactant in very low birth weight infants to prevent bronchopulmonary dysplasia. Turkish Journal of Pediatrics, (2020); 62(4):551-559. doi: 10.24953/turkjped.2020.04.004.

Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Nature reviews Disease primers, (2001); 163:1723–1729.

Jobe AJ. The new BPD: An arrest of lung development. Pediatrics Research, (1999);46:641–643.25.

Bancalari E, Claure N, Sosenko IR, editors. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Seminars in neonatology; (2003): Elsevier.

Hallman M, Merritt TA, Akino T, Bry K. Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. American Review of Respiratory Disease, (1991); 144:1376 –1384.

Ballard PL, Merrill JD, Godinez RI, Godinez MH, Truog WE, Ballard RA. Surfactant protein profile of pulmonary surfactant in premature infants. American Journal of Respiratory and Critical Care Medicine, (2003); 168:1123–1128.

Smedsaas‐Löfvenberg A, Nilsson K, Moa G, Axelsson IJAP. Nebulization of drugs in a nasal CPAP system. Acta Paediatrica, (1999);88(1):89-92.

Bassler D, Plavka R, Shinwell ES, Hallman M, Jarreau P-H, Carnielli V, et al. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. New England Journal of Medicine, (2015); 373(16):1497-506.

Mohamed HS, Meguid MM. Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome: Randomized controlled study. Saudi Journal of Anaesthesia, (2017); 11(1): 9.

Basu S, Kumar A, Bhatia B, Satya K, Singh TJ. Role of steroids on the clinical course and outcome of meconium aspiration syndrome—a randomized controlled trial. Journal of tropical pediatrics, (2007); 53(5):331-7.

Festic E, Carr GE, Cartin–Ceba R, Hinds RF, Banner–Goodspeed V, Bansal V, et al. Randomized clinical trial of a combination of an inhaled corticosteroid and beta agonist in patients at risk of developing the acute respiratory distress syndrome. Critical Care Medicine, (2017);45(5):798.

Santos AR, Heidemann SM, Walters III HL, Delius REJPCCM. Effect of inhaled corticosteroid on pulmonary injury and inflammatory mediator production after cardiopulmonary bypass in children. Pediatric Critical Care Medicine, (2007); 8(5):465-9.

Bickel TJSM. Spreading dynamics of reactive surfactants driven by Marangoni convection. Soft Matter, (2019); 15(18):3644-8.

Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine, (2016); 193(1):86-95.

Yang CF, Jeng MJ, Soong WJ, Lee YS, Tsao PC, Tang RBJP, et al. Acute pathophysiological effects of intratracheal instillation of budesonide and exogenous surfactant in a neonatal surfactant-depleted piglet model. Pediatrics & Neonatology, (2010); 51(4):219-26.

Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. New England Journal of Medicine, (1999); 340(13):1005–1010.

Yeh TF, Lin HC, Chang CH, Wu TS, Su BH, Li TC, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics, (2008); 121(5): 1310-e8.

Sadeghnia A, Beheshti BK, Mohammadizadeh M. The effect of inhaled budesonide on the prevention of chronic lung disease in premature neonates with respiratory distress syndrome. International Journal of Preventive Medicine, (2018); 9:15.

Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine, (2016); 193(1):86-95.

Rohini Venkataraman MD et al: Intratracheal Administration of Budesonide‐Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta‐Analysis. Pediatric Pulmonology, (2017); 52(7): 23680.

Wen JJ, Wan X, Thacker J, Garg N. Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy. Basic to Translational Science, (2016); 1(4): 235-50.

Minji Heo, Ga Won Jeon .Intratracheal administration of budesonide with surfactant in very low birth weight infants to prevent bronchopulmonary dysplasia. Turkish Journal of Pediatrics, (2020); 62(4): 551-559.

Kuo HT, Lin HC, Tsai CH, Chouc IC, Yeh TF. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. The Journal of Pediatrics, (2010); 1; 156(4):537-41.




DOI: http://dx.doi.org/10.62940/als.v10i2.1856

Refbacks

  • There are currently no refbacks.